Table 5 Risk of castration-resistant prostate cancer (CRPC) treatment to end due to inefficacy by statin use at the time of treatment line initiation in a cohort of prostate cancer patients treated with androgen deprivation therapy.
From: Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
Risk of first line CRPC treatment to end as ineffective by statin use status | Risk of second line CRPC treatment to end as ineffective by statin use status | |||
|---|---|---|---|---|
Age-adjusted | Multivariable-adjusted* | Age-adjusted | Multivariable-adjusted* | |
All treatment choices | 1.18 (0.68–2.06) | 1.04 (0.58–1.88) | 0.83 (0.34–2.00) | 0.99 (0.38–2.59) |
Enzalutamide or abiraterone | 1.16 (0.43–3.12) | 0.63 (0.16–2.49) | 2.97 (0.89–9.95) | 2.52 (0.72–8.76) |
Docetaxel or kabazitaxel | 1.04 (0.38–2.83) | 1.02 (0.37–2.80) | 0.43 (0.05–3.77) | 1.65 (0.17–16.32) |
Other | 1.05 (0.41–2.71) | 1.42 (0.50–3.98) | 0.55 (0.07–4.57) | 0.46 (0.05–4.22) |
